Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in Chicago
October 17, 2024
Results from the Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During Retina Subspecialty Day
Positive Data from TEASE Program in Stargardt Disease to be Presented
CAMBRIDGE, Mass., October 17, 2024 – Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of geographic atrophy secondary to age-related macular degeneration (SAGA) and Stargardt disease (TEASE) will be presented at the 128th annual meeting of the American Academy of Ophthalmology (AAO) being held in Chicago October 18-21, 2024. Oral Presentations:- Gildeuretinol in Geographic Atrophy: Results from SAGA, a 2-year, Randomized, Double-masked, Placebo-controlled Study (Alexander Melamud, M.D.). Retina Subspecialty Day 2024, October 18, 4:25 p.m. – 4:32 p.m. CDT; Day 1, Session RET11, Section IX: Late Breaking Developments, Part 1, Arie Crown, McCormick Place
- Deuterated Vitamin A Preserves Vision in Stargardt Disease (TEASE Study), (Christine Nichols Kay, M.D.). October 20, 4:01 p.m. – 4:13 p.m. CDT; Session SYM51, New Retinal Therapies: Recent Outcomes From Clinical Trials, S406A, McCormick Place